Innovation and Knowledge Centre Regenerative Therapies and Devices Tranche 2 IKC RTD

再生疗法和装置创新和知识中心建立了一个可持续的平台，以解决再生疗法和装置新技术的创造问题。通过战略优先安排和关键技术领域的发展，我们试图在成本限制日益增加的复杂全球市场中，以更高的可靠性促进它们的加速采用。促进身体组织再生的疗法和设备有可能给医疗保健带来革命性的变化，并成为经济增长的催化剂，在医疗保健技术领域创造一个新的商业部门。通过开发新的创新基础设施和实践，提供重要的临床、健康和行业成果，IKCRTD建立了大学及其合作伙伴(行业、NHS和中介/用户)的文化和研究格局。在运营的头两年，IKCRTD建立了一个高质量的研究和创新平台，其基础是：建立了8500万新的研究收入，建立了学术供应链，拥有250名研究人员的新研究中心大学投资建造了一个新的医疗技术创新大楼，以创建一个激励创新的社区。通过以下方式嵌入成功的可持续创新：开发强大的可持续发展模式战略确定和优先处理关键市场部门，帮助开发35种已投放市场的新产品，发展跨学术、行业和临床合作伙伴的创新文化。通过以下方式建立重要的形象和声誉：重要的政治访问和媒体报道通过与Regener8的战略结盟扩大了整个英国的覆盖范围和联系8建立了一个医疗技术品牌，以促进公司，通过以下方式建立强有力的创新管理：招募和建立核心团队并建立治理结构建立创新管道、阶梯大门和项目进展标准一个定义的知识产权组合、11个概念验证和4个直接资助的共同开发项目107个合作创新项目的管道与34个公司合作伙伴接触到更广泛的网络，200多家潜在的合作公司。

The Innovation and Knowledge Centre in Regenerative Therapies and Devices has established a sustainable platform to address the creation of new technologies in Regenerative Therapies and Devices. Through strategic prioritisation and development of key technology areas we have sought to promote their accelerated adoption, with increased reliability, within a complex global marketplace with increasing cost constraints. Therapies and devices which facilitate the regeneration of body tissues offer the potential to revolutionise healthcare and be a catalyst for economic growth, creating a new business sector within healthcare technology. The IKCRTD has built upon the culture and research landscape of the University and its partners (industry, NHS and intermediaries/users) through the development of new innovation infrastructure and practices which deliver major clinical, health and industry outcomes.In the first two years of operation IKCRTD has:Established a high quality research and innovation platform that is underpinned by: £85m new research income Established academic supply chain, new research centre with 250 researchers University investment for a new Medical Technologies Innovation building to create a community to stimulate innovation.Embedded successful sustainable innovation through: The development of a robust sustainability model Strategic identification and prioritisation of key market sectors Contributing to the development of 35 new products that have reached the market Developing a culture of innovation across academic, industry and clinical partnerships.Established a significant profile and reputation through: Significant political visits and media coverage Widened reach and connections across the UK through strategic alignment with Regener8 Established a Medical Technologies brand to facilitate companies, academics and clinical partners to collaborate with the centre.Established robust innovation management through: Recruited and established core team and set up governance structures Established an innovation pipeline, stage gates and the criteria for project progression A defined IP portfolio, 11 Proof of Concept and 4 Co-Development projects directly funded Pipeline of 107 collaborative innovation projects Engagement with 34 company partners Access to wider network of 200 plus potential collaborative companies.